Similar reductions in cell viability were obtained with other triple negative BCC, namely MDA-MB-468, SUM159, and BT-20, but there were little or no effects of the D1R agonists on ER/PR-positive T47D or MCF7 cells. This evidence concerns the gene DRD1 and skin basal cell carcinoma.